Evidence map›Paper›PMID 33398681›Full record

SynthesisMolecular biology reports2021

The expression of Galectin-3 in breast cancer and its association with metastatic disease: a systematic review of the literature.

Ioannis Boutas, Anastasios Potiris, Evangelos Makrakis, Pantelis Messaropoulos, Georgios-Konstantinos Papaioannou, Sophia Ν Kalantaridou

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. IntratumoralACS omega · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ioannis Boutas *Third Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
Anastasios Potiris *Third Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece. apotiris@med.uoa.gr.ORCID http://orcid.org/0000-0001-7716-1521
Evangelos MakrakisThird Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
Pantelis MessaropoulosThird Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
Georgios-Konstantinos PapaioannouThird Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
Sophia Ν KalantaridouThird Department of Obstetrics and Gynecology, Attikon University Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common form of cancer and the second highest cause of cancer mortality in female patients. The significance of the expression of Galectin-3 has been correlated with various malignancy types and in data from several research papers, the expression of Galectin-3 has been associated with the progression and metastasis of breast cancer. In the present study, the authors' goal is to identify whether the expression of Galectin-3 in breast cancer can be associated with the presence and/or recurrence of a metastatic disease. Both Scopus and PubMed databases were utilized, by inputting the following combination of keywords: (((Breast) AND Metastasis)) AND ((Galectin 3) OR Galectin-3). The time of publication and text availability were not considered when searching the databases and all relevant articles in English were initially accepted. We included one case-control study, three retrospective case studies and one retrospective cohort study. In two of the included studies, the levels in concentration of Galectin-3 were not correlated with a significant difference in prognosis. In two studies, the lacking in expression of Galectin-3 was associated with a worse prognosis and in one of the studies selected, the elevated levels of Galectin-3 were correlated with recurrence of disease in triple negative breast cancer cases. For most of the studies selected for this review, the results were contradictory in regard to the role of Galectin-3 for prognosis and metastatic potential in female breast cancer patients. It is still unclear, whether Galectin-3 can be used as a prognostic marker for advanced breast cancer disease.

Indexed as

AdultBlood ProteinsBreast NeoplasmsCohort StudiesFemaleGalectinsGene ExpressionHumansLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisSurvival AnalysisBlood ProteinsGalectinsLGALS3 protein, humanBreast cancerGalectin-3MetastasisMetastatic diseaseRecurrence

Identifiers

PMID33398681
OpenAlexW3118294884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.